

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) An antibody or antibody ~~derivative against~~ fragment thereof that binds Factor IX or Factor IXa ~~factor IX/factor IXa which and~~ increases the procoagulant activity of ~~FIXa~~ Factor IXa.
2. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 1, ~~wherein said antibody or antibody derivative that~~ increases the procoagulant activity of ~~FIXa~~ Factor IXa in the presence of FVIII Factor VIII inhibitors.
3. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 1 wherein ~~said the~~ antibody is ~~selected from the group consisting of an~~ IgG, IgM, IgA and or IgE ~~antibodies~~ antibody.
4. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 1, wherein said antibody or antibody ~~derivative~~ fragment is selected from the group consisting of ~~monoclonal antibodies, antibody fragments, chimeric antibodies, humanized antibodies, single chain antibodies, bispecific antibodies, diabodies, and di-, oligo- or multimers thereof~~ a monoclonal antibody, a chimeric antibody, a humanized antibody, a single chain antibody, a bispecific antibody, a diabody, and di-, oligo- or multimers thereof.
- 5-6. (cancelled)
7. (currently amended) ~~An antibody or antibody derivative according to claim 1, wherein a~~ A CDR3 peptide of the antibody or antibody derivative fragment according to claim 1 consisting of ~~comprises~~ an amino acid sequence selected from the group consisting of:

~~Cys-X-X-Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr-X-X-Cys, (SEQ ID NO:105) wherein X may be any desired amino acid;~~

Tyr-Gly-Asn-Ser-Pro-Lys-Gly-Phe-Ala-Tyr (SEQ ID NO:5); and

Asp-Gly-Gly-His-Gly-Tyr-Gly-Ser-Ser-Phe-Asp-Tyr (SEQ ID NO:6).

8. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 1, wherein the variable region of said antibody or antibody ~~derivative~~ fragment comprises amino acids 1-119 and/or amino acids 135-242 as listed in SEQ ID NO:82.

9. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 8, ~~wherein said antibody or antibody derivative that~~ additionally comprises an artificial linker sequence.

10. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 1, wherein the variable region of said antibody or antibody ~~derivative~~ fragment comprises amino acids 1-121 and/or amino acids 137-249 as listed in SEQ ID NO:84.

11. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 10, ~~wherein said antibody or antibody derivative that~~ additionally comprises an artificial linker sequence.

12. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 1, wherein the variable region of said antibody or antibody ~~derivative~~ fragment comprises amino acids 1-122 and/or amino acids 138-249 as listed in SEQ ID NO:86.

13. (currently amended) ~~An~~ The antibody or antibody ~~derivative~~ fragment according to claim 12, ~~wherein said antibody or antibody derivative that~~ additionally comprises an artificial linker sequence.

14. (currently amended) ~~A hybridoma~~ A hybridoma cell line secreting an antibody ~~or antibody derivative against factor IX/factor IXa~~ that binds Factor IX or Factor IXa ~~and increases the procoagulant activity of Factor IXa according to claim 1.~~

15. (currently amended) ~~A hybridoma~~ The hybridoma cell line according to claim 14, ~~wherein said cell line~~ that is selected from the group consisting of cell lines having ECACC deposit numbers 99090924, 99090925, 99090926, 99121614, 99121615, 99121616, 99121617, 99121618, 99121619 and 99121620.

16. (currently amended) An antibody ~~or antibody derivative which~~ that is secreted by a hybridoma cell line according to claim 14.

17. (cancelled)

18. (currently amended) A ~~pharmaceutical~~ preparation comprising an antibody or antibody derivative fragment according to claim 1 and a pharmaceutically acceptable carrier.

19. (currently amended) ~~A preparation~~ The preparation according to claim 18, additionally comprising ~~factor~~ Factor IX α and/or ~~factor~~ Factor IX β .

20-22. (cancelled)

23. (currently amended) A method of obtaining an antibody ~~or antibody derivative which~~ that ~~interacts with factor IX/factor IXa~~ Factor IX or Factor IXa and increases the procoagulant activity of Factor IXa, comprising the steps of:

immunizing an immunocompetent mouse with an antigen selected from the group consisting of FIX, FIX α , FIX β or fragments thereof,

isolating spleen cells of the immunized mouse,

producing hybridoma cells,
screening the hybridoma cell supernatants for an increase in the procoagulant activity of Factor IXa, isolating and purifying the ~~antibodies or antibody derivatives~~ antibody from a supernatant from the hybridoma cell cells supernatants which exhibit an increase in the procoagulant activity of ~~factor~~ Factor IXa.

24-25. (canceled)

26. (currently amended) ~~An~~ The antibody or antibody derivative fragment according to claim 4, ~~which~~ wherein the antibody fragment is a single chain antibody.

27. (currently amended) The antibody or antibody derivative fragment according to claim 4, ~~which~~ wherein the antibody is a humanized antibody.

28. (canceled)

29. (currently amended) ~~An~~ The antibody or antibody derivative fragment according to claim 2 wherein said the antibody is selected from the group consisting of an IgG, IgM, IgA ~~and or~~ IgE antibodies antibody.

30. (new) The antibody or antibody fragment of claim 1, wherein the antibody fragment comprises a CDR3 peptide.

31. (new) The antibody or antibody fragment of claim 1, wherein the antibody fragment is a CDR3 peptide.